ArticleMethods in molecular biology (Clifton, N.J.)2025
Multiplexed Epitope Mapping of HIV-1 Neutralizing Antibodies by Coupling Chemical Labeling of Cysteines to Deep Sequencing.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of neutralizing antibody (NAb) binding sites or epitopes on an antigen is a prerequisite for epitope-focused vaccine design strategies. HIV-1 infection is associated with polyclonal antibody responses comprising NAbs that target multiple epitopes on the envelope glycoprotein (Env), the primary target of the immune response. Current epitope mapping methods, such as X-ray crystallography and cryo-EM microscopy that rely on purified antigen-antibody complexes, fail to reliably deconvolute epitope specificities of polyclonal HIV-1 antibodies. We describe a method to map antigen-antibody binding sites at single residue resolution, using chemically masked cysteines coupled to deep sequencing. This was achieved by generating a panel of cysteine mutants of the HIV-1 Env antigen on the viral surface, followed by chemical labeling of cysteines using Cys-reactive probes that block antibody binding. Epitopes are inferred using assays that monitor viral infectivity in the absence and presence of NAbs, followed by deep sequencing. We successfully applied this technique to distinguish residues at the epitope from residues lying outside the epitope for several NAbs. The methodology is also able to accurately map epitopes of polyclonal NAbs from HIV-1-infected individuals and HIV-1-immunized animals. Here, we describe protocols to facilitate adoption of this methodology. Knowledge of polyclonal epitope specificities can provide useful insight into the nature of the antibody response elicited by the virus, which can be used to design better immunogens against HIV-1 and emerging viral pathogens.
Indexed as
Identifiers
40593424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.